<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00688116</url>
  </required_header>
  <id_info>
    <org_study_id>9090-01</org_study_id>
    <nct_id>NCT00688116</nct_id>
  </id_info>
  <brief_title>Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice-Weekly in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synta Pharmaceuticals Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synta Pharmaceuticals Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label dose escalation study of patients with solid tumors treated with STA-9090
      (ganetespib)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label Phase 1 dose-escalation study in patients with solid tumors treated
      with STA-9090 (ganetespib) to evaluate for safety, tolerance and efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of STA-9090 (ganetespib) in cancer patients via assessment of dose limiting toxicities and evaluation of Adverse Events in relation to Study Drug.</measure>
    <time_frame>Cycle 1</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ganetespib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STA 9090 (ganetespib)</intervention_name>
    <description>This is a dose-escalation study. The first cohort will consist of three patients who will receive 2 mg/m2 of STA 9090 (ganetespib) during a 1-hour infusion 2 times per week (e.g., [Monday, Thursday] or [Tuesday, Friday]) for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive 4, 7, 10, 14, 19, 25, 33, 40 and 48 mg/m2 provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Further dose increments will be approximately 20% over the previous dose level, until the maximum tolerated dose (MTD) is determined.</description>
    <arm_group_label>ganetespib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be documented to be refractory or not candidates for current approved
             therapies. - Must have anECOG status 0-2. - Peripheral neuropathy ?2.

          -  Must have acceptable organ and marrow function per protocol parameters.

          -  No clinically significant ventricular arrythmias or ischemia.

        Exclusion Criteria:

          -  Must not be pregnant or breastfeeding. -No chemotherapy or radiation within 3 weeks..

          -  No previous radiation to &gt;25% of total bone marrow.

          -  No previous high dose chemotherapy with autologous or allogeniec hematopoietic stem
             cell transplantation.

          -  No primary brain tumors or active brain metastases.

          -  No use of any investigational agents within 4 weeks.

          -  No treatment with chronic immunosuppressants.

          -  No uncontrolled, intercurrent illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center (BIDMC) - Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2008</study_first_posted>
  <last_update_submitted>September 17, 2014</last_update_submitted>
  <last_update_submitted_qc>September 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic cancer</keyword>
  <keyword>solid tumor</keyword>
  <keyword>histologically or cytologically confirmed non-hematological malignancy that is metastatic or unresectable</keyword>
  <keyword>STA-9090</keyword>
  <keyword>ganetespib</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

